Abstract
Realization of part of clinical trial called: A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema